Fig. 7

Effects of PIASy silencing on lethal arrythmias during myocardial I/R. a Schematic diagram showing VT and VF during I/R. b-c Duration values of sustained VT (b) and VF (c) after I/R. d Arrhythmia scores in I/R-injured rats with PIASy-shRNA or Scramble-shRNA treatments. e–g Episodes of VT (e), sustained VT (f), and VF (g) within consecutive 5 min blocks after ligation of the left anterior descending coronary artery. Values are expressed as the mean ± standard error of the mean (n = 10). ^*P < 0.05, ^**P < 0.01. Kruskal–Wallis tests were performed in b, c, and e–g; one-way ANOVA was performed in d. AAV9 adeno-associated virus subtype 9, ANOVA analysis of variance, ECG electrocardiography, I/R ischemia/reperfusion, PIASy protein inhibitor of activated STAT Y, shRNA short hairpin RNA, VF ventricular fibrillation, VT ventricular tachycardia